# Quastella

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quastella

- Industry: Biotechnology
- Headquarters: Nagoya-shi, Japan
- Website: www.quastella.com
- Latest round: Seed (Oct 18, 2023)
- Investors on record: 2

## About

Based in Nagoya, Japan, and founded in 2019, Quastella Inc. provides AI-based solutions to analyze, improve, and standardize the process of cultivating living cells. In October 2023, Quastella Inc. raised seed funding from investors Incubate Fund and SSS Capital. As of October 2023, the company is led by CEO Yuto Takemoto.

Quastella's flagship product, Cell Culture DX, is a control technology designed to cater to a wide spectrum of industries. It finds application in drug discovery, cosmetics, pesticides, regenerative medicine, cellular agriculture, and more. The product enables users to optimize their cell culture processes, ensuring the highest standards of quality and efficiency. In addition, the company also offers Cytometa, a cell quality control platform designed to enhance the value of cell imaging. By leveraging AI and data-driven insights, Cytometa empowers researchers and professionals to improve the quality and accuracy of cell image analysis.

## Funding rounds

- Seed, Oct 18, 2023 — Incubate Fund, SSS Capital

## Investors

- Incubate Fund (https://capitalatlas.ai/funds/incubate-fund) — Seed
- SSS Capital (https://capitalatlas.ai/funds/sss-capital) — Seed